- Milestone Pharmaceuticals developed CARDAMYST, a nasal spray for PSVT.
- An estimated 2 million people in the U.S. have PSVT.
- PSVT leads to 140,000-525,000 ER visits annually in the U.S.
- Aptar's Bidose system ensures reliable drug access for patients.
Introduction
Milestone Pharmaceuticals has developed CARDAMYST, the first FDA-approved self-administered nasal spray for treating Paroxysmal Supraventricular Tachycardia (PSVT). This innovative treatment utilizes Aptar's Bidose nasal delivery system.
PSVT Prevalence
PSVT is a type of arrhythmia affecting approximately two million people in the United States. It is characterized by sudden episodes of rapid heartbeats, often exceeding 150 to 200 beats per minute. This condition results in an estimated 140,000 to 525,000 emergency department visits and 40,000 to 120,000 inpatient hospitalizations annually in the U.S.
Drug Delivery System
Aptar CSP Technologies collaborated with Milestone Pharmaceuticals to create a custom-designed, patient-friendly polypropylene container closure system for CARDAMYST. This system securely houses two Bidose delivery mechanisms, preventing accidental activation or dropping, and ensuring reliability when needed.
Regulatory Support
The development of CARDAMYST benefited from Aptar Pharma's Drug Services, which offers a comprehensive portfolio of stage-specific development packages. Aptar's Regulatory Affairs experts and analytical scientists assist customers in addressing regulatory needs to expedite approval.
